<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Cellectis will shed 70% of workforce as part of in vivo pivot — Live Feed</title><link>https://www.live-feeds.com/feed/cellectis-will-shed-70-of-workforce-as-part-of-in-vivo-pivot</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/cellectis-will-shed-70-of-workforce-as-part-of-in-vivo-pivot/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Cellectis Cuts 70% of Workforce in Strategic Pivot</title><link>https://www.live-feeds.com/feed/cellectis-will-shed-70-of-workforce-as-part-of-in-vivo-pivot</link><guid isPermaLink="false">https://www.live-feeds.com/feed/cellectis-will-shed-70-of-workforce-as-part-of-in-vivo-pivot#u205774</guid><pubDate>Tue, 17 Nov 2026 18:15:35 +0000</pubDate><description>Cellectis will shed 70% of its workforce as part of an in vivo pivot, according to corporate announcements and recent reporting. The restructuring arrives alongside financial updates showing third-quarter results for 2026. Revenue fell to $14.8 million alongside a wider nine-month loss, while earnings missed estimates by $0.42. The company outlined its ongoing business adjustments during its recent Q3 earnings call, detailing the operational shifts required to refocus its strategy toward in vivo therapeutic development.Why it mattersThe massive staff reduction marks a major strategic shift for</description></item>
</channel></rss>